Cyclophosphamide - Open Access .click

Results 1 to 10 of about 257,826 (338)

BMJ, 1963
Cyclophosphamide, a recently-developed alkylating agent that may be administered orally, intramuscularly, and intravenously, was given to 135 patients with a wide variety of malignant diseases. Significant benefit was obtained in patients with lymphomas and leukemias as well as malignant melanoma, multiple myeloma, and carcinoma of the ovaries ...
Jesse L. Steinfeld, Merton J. Alexander, Joel Solomon +2 more
+7 more sources

Cyclophosphamide and the kidney [PDF]

Cancer, 1974
The effect of cyclophosphamide on renal function was studied in 17 normally hydrated patients with cancer. No nephrotoxic effects were observed. High-dose cyclophosphamide (⩾50 mg/kg body weight) did, however, impair water excretion as manifested by weight gain, hyponatremia, and inappropriately concentrated urine.
Hayden Braine +4 more
openaire +3 more sources

Metabolism of cyclophosphamide [PDF]

Cancer, 1967
The in vivo activation of cyclophosphamide (Endoxan) to cytostatic and alkylating metabolites has been studied. Endoxan is metabolized to the weak anion by microsomal dealkylation in the rat's liver; this product is the first alkylating metabolite.
N. Brock, H.-J. Hohorst
openaire +3 more sources

Cyclophosphamide for multiple sclerosis

Cochrane Database of Systematic Reviews, 2002
Multiple sclerosis is a presumed cell-mediated autoimmune disease of the central nervous system. Cyclophosphamide (CFX) is a cytotoxic and immunosuppressive agent, used in systemic autoimmune diseases. Controversial results have been reported on its efficacy in MS.
L, La Mantia +5 more
openaire +4 more sources

Azathioprine, cyclophosphamide and chlorambucil

Baillière's Clinical Rheumatology, 1990
Immunosuppressive agents serve a major role in the management of once-fatal conditions such as the systemic necrotizing vasculitides, but they are also being used in more common, chronic inflammatory disorders such as rheumatoid arthritis. The drugs are all capable of reducing cell division but they differ in their modes of action.
Luqmani, R, Palmer, R, Bacon, P
openaire +3 more sources

Cyclophosphamide and the bladder. [PDF]